Atrium Therapeutics Inc
NAS:RNAHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG$7.98+4.86%At closeAt close · Wed 21 Oct · ≈ AED 29.31 · Market cap $177.76M · Next earnings Thu 12 Nov
| USD millions | FY2023 | FY2024 | FY2025 | Trend | YoY |
|---|---|---|---|---|---|
| Net income | — | — | (49.5) | — | |
| Depreciation & amortization | 0.1 | 0.2 | 0.3 | +87.8% | |
| Stock-based compensation | — | — | 7.7 | — | |
| Change in working capital | 59.9 | (12.9) | (0.2) | +98.4% | |
| Operating cash flow | 56.4 | (22.6) | (41.1) | −82.4% | |
| Capital expenditure | (0.3) | (0.3) | (1.4) | −443.2% | |
| Acquisitions | — | — | 0.0 | — | |
| Investing cash flow | — | — | (1.4) | — | |
| Dividends paid | 0.0 | 0.0 | 0.0 | — | |
| Share buybacks | — | — | 0.0 | — | |
| Debt issued / repaid | — | — | 0.0 | — | |
| Financing cash flow | — | — | 42.6 | — | |
| Free cash flow | 56.1 | (22.8) | (42.6) | −86.6% | |
| Net change in cash | — | — | 0.0 | — |
USD millionsUpdated Thu 13 Aug ·
ⓘ
Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.
